Oragenics
OGEN
11 hedge funds and large institutions have $2.73M invested in Oragenics in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
57% more funds holding
Funds holding: 7 → 11 (+4)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
11% less capital invested
Capital invested by funds: $3.06M → $2.73M (-$328K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$113K |
| 2 |
VF
Virtu Financial
New York
|
+$71K |
| 3 |
MP
MSD Partners
New York
|
+$63.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.2K |
| 5 |
Barclays
London,
United Kingdom
|
+$18.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$39.5K |
| 2 |
Citigroup
New York
|
-$2K |
OGEN Hedge Fund Activity: Q2 2018 in Review
11 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Oragenics (OGEN) for Q2 2018, worth a combined $2.73M — down 11% from $3.06M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new OGEN positions and 0 closed out — a net gain of 4 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $113K. The largest seller was IFP Advisors, cutting an estimated $39.5K.
- 11 institutional investors held Oragenics (OGEN) as of Q2 2018, up from 7 in Q1 2018.
- Funds reported $2.73M of Oragenics stock for Q2 2018, down 11% quarter-over-quarter.
- 4 funds opened new Oragenics positions in Q2 2018 and 0 closed out, a net change of +4 holders.
- The largest Oragenics buyer in Q2 2018 was Morgan Stanley, an estimated $113K added.
- The largest Oragenics seller in Q2 2018 was IFP Advisors, an estimated $39.5K sold.
Based on aggregated 13F filings for Q2 2018.